News & Analysis on Clinical Trial Services & Contract Research And Development
PhRMA, EFPIA, JPMA and the IFPMA have adopted a “joint position” that calls on member companies to submit summaries of all Phase III studies and those of “significant medical importance” for publication in peer reviewed journals.
Evonik has strengthened its precious metal powder catalysts business, opening a production site in Shanghai, China and buying an Indian company.
The ACRO says greater regulatory harmonization, expansion of trial registries and clarification of liability issues are needed to address the “alarming” drop in number of investigators participating in trials in US and Europe
Emergent Technologies’ particle engineering unit, Enavail, will set up a new contract manufacturing facility in Texas, US.
BioScale has secured $25m (€21m) to fund commercialisation of its ViBE protein analytics systems.
Bristol-Myers Squibb (B-MS) has inked deals with Icon and Parexel to support the large volume of clinical development work it expects to perform in coming years.
The DCGI has banned import of raw materials from 10 Chinese companies which lacked mandatory manufacturing standards, according to The Economic Times of India.
Pall and New Brunswick have teamed up to develop and supply new disposable bioreactor technologies, targeting growing demand for products that improve quality and reduce cost of biomanufacturing.